Retatrutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic triple-hormone peptide (GLP-1, GIP, glucagon) marketed for record-setting weight loss and metabolic improvement. Human evidence is strong: major weight loss, liver fat reduction, and blood sugar gains, though secondary benefits are less certain. GI side effects are common, long-term safety data are limited, and a theoretical thyroid tumor risk applies to the class. Not FDA-approved; most supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)
HighConfirmed in a Phase 2 randomized trial; the higher Phase 3 figures are unpublished company data.
Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks
HighPhase 2a trial: 86% on the highest dose reached normal liver fat by week 24.
Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)
HighPhase 2 randomized trial showed a 2.02% HbA1c drop, later confirmed in a 2026 Phase 3 trial.
Evidence limits
- Evidence Level
- Strong Evidence
Phase 2 results published in NEJM, Lancet, and Nature Medicine. Phase 3 TRIUMPH program has 8+ trials enrolling 5,800+ participants. Five positive Phase 3 studies reported: TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-1. Not yet FDA-approved.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteTriple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 component carries pancreatitis risk.
Severe gastroparesis
HighGLP-1 component significantly slows gastric emptying.
General cautions
Pregnancy
AbsoluteInvestigational — no reproductive safety data.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events
HighDysesthesia (altered skin sensation)
ModerateDose-dependent increase in heart rate
ModeratePancreatitis (rare)
LowGallbladder events (cholelithiasis)
ModerateThyroid C-cell tumor risk (GLP-1 class warning)
TheoreticalLimited long-term safety data
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.